PMID- 27246670
OWN - NLM
STAT- MEDLINE
DCOM- 20171113
LR  - 20221207
IS  - 1932-2968 (Electronic)
IS  - 1932-2968 (Linking)
VI  - 11
IP  - 1
DP  - 2017 Jan
TI  - Impact of Disease Management Programs on HbA1c Values in Type 2 Diabetes Patients 
      in Germany.
PG  - 117-122
LID - 10.1177/1932296816651633 [doi]
AB  - BACKGROUND: The aim was to analyze the impact of disease management programs on 
      HbA1c values in type 2 diabetes mellitus (T2DM) patients in Germany. METHODS: 
      This study included 9017 patients followed in disease management programs (DMPs) 
      who started an antihyperglycemic treatment upon inclusion in a DMP. Standard care 
      (SC) patients were included after individual matching (1:1) to DMP cases based on 
      age, gender, physician (diabetologist versus nondiabetologist care), HbA1c values 
      at baseline, and index year. The main outcome was the share of patients with 
      HbA1c <7.5% or 6.5% after at least 6 months and less than 12 months of therapy in 
      DMP and SC groups. Multivariate logistic regression models were fitted with HbA1c 
      level as a dependent variable and the potential predictor (DMP versus SC). 
      RESULTS: The mean age was 64.3 years and 54.7% of the patients were men. The mean 
      HbA1c level at baseline was equal to 8.7%. In diabetologist practices, 64.7% of 
      DMP patients and 55.1% of SC patients had HbA1c levels <7.5%, while 23.4% of DMP 
      patients and 16.9% of SC patients had HbA1c levels <6.5% ( P values < .001). By 
      comparison, in general practices, 72.4% of DMP patients and 65.7% of SC patients 
      had HbA1c levels <7.5%, while 29.0% of DMP patients and 25.4% of SC patients had 
      HbA1c levels <6.5% ( P values < .001). DMPs increased the likelihood of HbA1c 
      levels lower than 7.5% or 6.5% after 6 months of therapy in both diabetologist 
      and general care practices. CONCLUSION: The present study indicates that the 
      enrollment of T2DM patients in DMPs has a positive impact on HbA1c values in 
      Germany.
FAU - Kostev, Karel
AU  - Kostev K
AD  - 1 IMS Health, Frankfurt, Germany.
FAU - Rockel, Timo
AU  - Rockel T
AD  - 1 IMS Health, Frankfurt, Germany.
FAU - Jacob, Louis
AU  - Jacob L
AD  - 2 Department of Biology, Ecole Normale Superieure de Lyon, Lyon, France.
LA  - eng
PT  - Journal Article
DEP - 20160710
PL  - United States
TA  - J Diabetes Sci Technol
JT  - Journal of diabetes science and technology
JID - 101306166
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Aged
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Disease Management
MH  - Female
MH  - Germany
MH  - Glycated Hemoglobin/*analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Middle Aged
PMC - PMC5375061
OTO - NOTNLM
OT  - DMP
OT  - HbA1c
OT  - disease management program
OT  - type 2 diabetes
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2016/06/02 06:00
MHDA- 2017/11/14 06:00
PMCR- 2017/07/10
CRDT- 2016/06/02 06:00
PHST- 2016/06/02 06:00 [pubmed]
PHST- 2017/11/14 06:00 [medline]
PHST- 2016/06/02 06:00 [entrez]
PHST- 2017/07/10 00:00 [pmc-release]
AID - 1932296816651633 [pii]
AID - 10.1177_1932296816651633 [pii]
AID - 10.1177/1932296816651633 [doi]
PST - ppublish
SO  - J Diabetes Sci Technol. 2017 Jan;11(1):117-122. doi: 10.1177/1932296816651633. 
      Epub 2016 Jul 10.